Cabaletta Bio (CABA) Competitors $1.18 -0.02 (-1.26%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. TSHA, ATYR, TECX, CMPX, AMLX, AQST, ATAI, TERN, PROK, and GOSSShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Taysha Gene Therapies (TSHA), Atyr PHARMA (ATYR), Tectonic Therapeutic (TECX), Compass Therapeutics (CMPX), Amylyx Pharmaceuticals (AMLX), Aquestive Therapeutics (AQST), Atai Life Sciences (ATAI), Terns Pharmaceuticals (TERN), ProKidney (PROK), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Taysha Gene Therapies Atyr PHARMA Tectonic Therapeutic Compass Therapeutics Amylyx Pharmaceuticals Aquestive Therapeutics Atai Life Sciences Terns Pharmaceuticals ProKidney Gossamer Bio Cabaletta Bio (NASDAQ:CABA) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk. Is CABA or TSHA more profitable? Cabaletta Bio has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. Cabaletta Bio's return on equity of -50.10% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Taysha Gene Therapies -229.67%-106.36%-49.16% Which has more risk & volatility, CABA or TSHA? Cabaletta Bio has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Do institutionals & insiders hold more shares of CABA or TSHA? 77.7% of Taysha Gene Therapies shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate CABA or TSHA? Cabaletta Bio presently has a consensus target price of $21.00, suggesting a potential upside of 1,732.46%. Taysha Gene Therapies has a consensus target price of $6.63, suggesting a potential upside of 436.44%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, CABA or TSHA? Cabaletta Bio has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.34-0.49Taysha Gene Therapies$8.33M30.38-$111.57M-$0.36-3.43 Does the MarketBeat Community favor CABA or TSHA? Taysha Gene Therapies received 12 more outperform votes than Cabaletta Bio when rated by MarketBeat users. Likewise, 77.54% of users gave Taysha Gene Therapies an outperform vote while only 72.52% of users gave Cabaletta Bio an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9572.52% Underperform Votes3627.48% Taysha Gene TherapiesOutperform Votes10777.54% Underperform Votes3122.46% Does the media refer more to CABA or TSHA? In the previous week, Cabaletta Bio had 34 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 35 mentions for Cabaletta Bio and 1 mentions for Taysha Gene Therapies. Cabaletta Bio's average media sentiment score of 0.47 beat Taysha Gene Therapies' score of 0.00 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 4 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCabaletta Bio beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks. Remove Ads Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.83M$2.98B$5.53B$7.50BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.5530.4323.1218.08Price / SalesN/A438.28360.0289.38Price / CashN/A168.6838.1634.64Price / Book0.213.646.473.99Net Income-$67.68M-$72.06M$3.21B$247.18M7 Day Performance-26.06%-9.02%-4.97%-4.25%1 Month Performance-34.89%-16.50%-0.14%-6.87%1 Year Performance-92.89%-31.37%6.19%-3.73% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.6693 of 5 stars$1.18-1.3%$21.00+1,687.2%-92.8%$59.37MN/A-0.5450Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownTSHATaysha Gene Therapies1.8869 of 5 stars$1.62-1.5%$6.63+310.2%-53.7%$331.08M$8.33M2.56180News CoverageGap DownATYRAtyr PHARMA2.5451 of 5 stars$3.73+1.2%$18.60+399.3%N/A$331M$235,000.00-3.9653Positive NewsGap DownTECXTectonic Therapeutic2.9234 of 5 stars$22.44+6.1%$77.75+246.5%N/A$326.87MN/A-3.76120CMPXCompass Therapeutics2.9979 of 5 stars$2.36+1.9%$11.38+383.0%-13.2%$325.66M$850,000.00-6.3620Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageAMLXAmylyx Pharmaceuticals2.6493 of 5 stars$3.68+0.7%$7.33+99.5%+33.5%$325.61M$87.37M-0.96200News CoverageGap DownAQSTAquestive Therapeutics1.2735 of 5 stars$3.28+2.0%$10.57+222.8%-34.5%$323.80M$57.56M-7.28160Analyst ForecastPositive NewsGap DownATAIAtai Life Sciences3.4389 of 5 stars$1.52+4.5%$9.00+494.1%-45.0%$300.43M$308,000.00-1.8780TERNTerns Pharmaceuticals3.8567 of 5 stars$3.47+3.4%$18.30+428.1%-61.2%$294.31MN/A-2.9440Gap DownPROKProKidney1.4287 of 5 stars$1.01+5.1%$5.00+395.5%-52.3%$294.29M$76,000.00-1.833Gap DownGOSSGossamer Bio3.5224 of 5 stars$1.29-7.6%$9.20+616.0%-15.2%$291.98M$114.70M-4.02180 Remove Ads Related Companies and Tools Related Companies TSHA Competitors ATYR Competitors TECX Competitors CMPX Competitors AMLX Competitors AQST Competitors ATAI Competitors TERN Competitors PROK Competitors GOSS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CABA Stock Free CABA Stock Alerts